更新于：2024-12-17
CNBG-Virogin Biotech (Shanghai) Ltd.
中生复诺健生物科技（上海）有限公司|
合资公司 | 私营公司 | 子公司|
2019|
中国上海市
更新于：2024-12-17
概览
标签
肿瘤
消化系统疾病
其他疾病
溶瘤病毒
预防性疫苗
mRNA疫苗
疾病领域得分
一眼洞穿机构专注的疾病领域
技术平台
公司药物应用最多的技术
靶点
公司最常开发的靶点
关联
靶点 |
作用机制 |
在研机构 |
原研机构 |
在研适应症 |
非在研适应症 |
最高研发阶段 |
首次获批国家/地区 |
首次获批日期 |
靶点 |
作用机制 |
在研机构 |
原研机构 |
在研适应症 |
非在研适应症 |
最高研发阶段 |
首次获批国家/地区 |
首次获批日期 |
靶点 |
作用机制 |
在研机构 |
原研机构 |
在研适应症 |
非在研适应症 |
最高研发阶段 |
首次获批国家/地区 |
首次获批日期 |
VG161联合卡瑞利珠单抗治疗晚期原发性肝细胞癌患者的开放的Ib/IIa 期临床试验
An Open-label Phase Ib/IIa Clinical Trial of VG161 Combined With Camrelizumab in the Treatment of Advanced Primary Hepatocellular Carcinoma
评价VG161治疗晚期骨与软组织肉瘤的有效性和安全性的单臂、多中心、开放的IIa期临床研究
100 项与 中生复诺健生物科技（上海）有限公司 相关的临床结果
登录后查看更多信息
登录后查看更多信息
2023-05-01Journal of medical virology
Combination of novel oncolytic herpesvirus with paclitaxel as an efficient strategy for breast cancer therapy
Article
作者: Shen, Yinan ; Deng, Xinyue ; Jia, Weiguo ; Zhao, Bin ; Zhang, Chaomei ; Ding, Jun ; Dai, Zhijun ; Leng, Qi ; WeiyangLou ; Xue, Dixuan ; Zhao, Ronghua ; Dong, Chenfang ; Yi, Ming ; Zhong, Guansheng
Abstract:
Background:
New strategies are needed to improve the treatment of patients with breast cancer (BC). Oncolytic virotherapy is a promising new tool for cancer treatment but still has a limited overall durable antitumor response. A novel replicable recombinant oncolytic herpes simplex virus type 1 called VG161 has been developed and has demonstrated antitumor effects in several cancers. Here, we explored the efficacy and the antitumor immune response of VG161 cotreatment with paclitaxel (PTX) which as a novel oncolytic viral immunotherapy for BC.
Methods:
The antitumor effect of VG161 and PTX was confirmed in a BC xenograft mouse model. The immunostimulatory pathways were tested by RNA‐seq and the remodeling of tumor microenvironment was detected by Flow cytometry analysis or Immunohistochemistry. Pulmonary lesions were analyzed by the EMT6‐Luc BC model.
Results:
In this report, we demonstrate that VG161 can significantly represses BC growth and elicit a robust antitumor immune response in a mouse model. The effect is amplified when combined with PTX treatment. The antitumor effect is associated with the infiltration of lymphoid cells, including CD4+ T cells, CD8+ T cells, and NK cells (expressing TNF and IFN‐γ), and myeloid cells, including macrophages, myeloid‐derived suppressor cells, and dendritic cell cells. Additionally, VG161 cotreatment with PTX showed a significant reduction in BC lung metastasis, which may result from the enhanced CD4+ and CD8+ T cell‐mediated responses.
Conclusions:
The combination of PTX and VG161 is effective for repressing BC growth by inducing proinflammatory changes in the tumor microenvironment and reducing BC pulmonary metastasis. These data will provide a new strategy and valuable insight for oncolytic virus therapy applications in primary solid or metastatic BC tumors.
Nature communications1区 · 综合性期刊
mRNA vaccines encoding fusion proteins of monkeypox virus antigens protect mice from vaccinia virus challenge
1区 · 综合性期刊
ArticleOA
作者: Yu, Zhibin ; Liu, Xiaohu ; Yang, Xiaoming ; Hua, Xianwu ; Jia, William ; Huang, Hongwei ; Zhang, Yuntao ; Xu, Jiang ; Ding, Jun ; Zhao, Ronghua ; Murad, Yanal M ; Hou, Fujun ; Song, Yingying
Abstract:
The recent outbreaks of mpox have raised concerns over the need for effective vaccines. However, the current approved vaccines have either been associated with safety concerns or are in limited supply. mRNA vaccines, which have shown high efficacy and safety against SARS-CoV-2 infection, are a promising alternative. In this study, three mRNA vaccines are developed that encode monkeypox virus (MPXV) proteins A35R and M1R, including A35R extracellular domain -M1R fusions (VGPox 1 and VGPox 2) and a mixture of encapsulated full-length mRNAs for A35R and M1R (VGPox 3). All three vaccines induce early anti-A35R antibodies in female Balb/c mice, but only VGPox 1 and 2 generate detectable levels of anti-M1R antibodies at day 7 after vaccination. However, all three mRNA vaccine groups completely protect mice from a lethal dose of vaccinia virus (VACV) challenge. A single dose of VGPox 1, 2, and 3 provide protection against the lethal viral challenge within 7 days post-vaccination. Long-term immunity and protection were also observed in all three candidates. Additionally, VGPox 2 provided better passive protection. These results suggest that the VGPox series vaccines enhance immunogenicity and can be a viable alternative to current whole-virus vaccines to defend against mpox.
Viruses-Basel
Vaccines' New Era-RNA Vaccine
作者: Pan, Xinping ; Yang, Guohuan ; Wu, Feifei ; Liao, Shimiao ; Jia, William ; Zhou, Wenshuo ; Liu, Lan ; Hou, Li ; Jiang, Linglei ; Zhang, Yuntao
A review.RNA vaccines, including conventional mRNA (mRNA) vaccines, circular RNA (circRNA) vaccines, and self-amplifying RNA (saRNA) vaccines, have ushered in a promising future and revolutionized vaccine development.The success of mRNA vaccines in combating the COVID-19 pandemic caused by the SARS-CoV-2 virus that emerged in 2019 has highlighted the potential of RNA vaccines.These vaccines possess several advantages, such as high efficacy, adaptability, simplicity in antigen design, and the ability to induce both humoral and cellular immunity.They also offer rapid and cost-effective manufacturing, flexibility to target emerging or mutant pathogens and a potential approach for clearing immunotolerant microbes by targeting bacterial or parasitic survival mechanisms.The self-adjuvant effect of mRNA-lipid nanoparticle (LNP) formulations or circular RNA further enhances the potential of RNA vaccines. However, some challenges need to be addressed.These include the technol.'s immaturity, high research expenses, limited duration of antibody response, mRNA instability, low efficiency of circRNA cyclization, and the production of double-stranded RNA as a side product.These factors hinder the widespread adoption and utilization of RNA vaccines, particularly in developing countries.This review provides a comprehensive overview of mRNA, circRNA, and saRNA vaccines for infectious diseases while also discussing their development, current applications, and challenges.
100 项与 中生复诺健生物科技（上海）有限公司 相关的药物交易
登录后查看更多信息
100 项与 中生复诺健生物科技（上海）有限公司 相关的转化医学
登录后查看更多信息
组织架构
使用我们的机构树数据加速您的研究。
登录
或
管线布局
2024年12月23日管线快照
管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期
临床1期
1
2
临床2期
登录后查看更多信息
当前项目
登录后查看更多信息
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
营收
使用 Synapse 探索超过 36 万个组织的财务状况。
登录
或
科研基金(NIH)
访问超过 200 万项资助和基金信息，以提升您的研究之旅。
登录
或
投资
深入了解从初创企业到成熟企业的最新公司投资动态。
登录
或
融资
发掘融资趋势以验证和推进您的投资机会。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用